Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Whatever name it takes when it goes down in history, the present “information age” will be inextricably linked to AI. It’s been so since around 2008, although popular perception needed time to catch up with the depth of the development.
AI holds the promise of improving gerontology by making it more predictive, personalized, preventive and participatory. However, to get there, an equal number of pronounced risks must be negotiated.
Patient-facing healthcare workers are neither softened nor hardened in their attitudes toward clinical decision support powered by AI when it’s instead called “AHI,” for augmented human intelligence.
An AI system trained to supply clinical decision support in the U.S. has proven adaptable for physicians treating patients with lung cancer on the other side of the globe.
The vast majority of patients with suspected melanoma—94%—would welcome the use of AI as an augmenter of their dermatologist’s diagnostic skills. And more than 40% would trust their diagnosis to a standalone AI system.
Cross-Atlantic researchers have developed two AI models that are fast and accurate at screening for COVID-19, offering hospitals potential options when lab testing is backed up or unavailable.
